Plate Nº 90 · recorded November 17, 2026

Health & Medicine ResearchReported finding

One-shot gene editing lowered LDL cholesterol 53% in early trial

An early 15-person trial found one CTX310 injection cut LDL cholesterol by 53% at the highest dose for a year, but long-term safety, cost and access remain unresolved.

By Elena Vasquez5 min read1,041 words

In brief

  1. A 15-person trial found a 53% LDL cholesterol reduction in the highest-dose CTX310 group, with reductions still present at one year.
  2. Experts compared the 53% result with the roughly 50% reduction daily statins can achieve.
  3. A separate 2026 VERVE-102 trial enrolled 35 people with heterozygous FH and reported a 62% LDL reduction at the highest dose.
  4. About 90 people across the US, UK, Australia and New Zealand will receive one CTX310 dose in a trial assessing efficacy and safety for one year.
  5. HoFH affects about 1 in 300,000 people, while heterozygous FH affects about 1 in 300.
This landmark new cholesterol treatment can cut levels by half after one dose, say experts
Plate Nº 90This landmark new cholesterol treatment can cut levels by half after one dose, say experts — geraldoswald62 / pixabay

By Elena Vasquez

A single injection of the experimental gene-editing drug CTX310 lowered LDL, or “bad” cholesterol, by 53% in the highest-dose group of a 15-person study, and all 15 participants still had reduced LDL after one year.

The New England Journal of Medicine study found the 53% decrease was roughly comparable to the 50% reduction experts say daily statin pills can deliver. CTX310 remains experimental and must undergo long-term safety testing before approval. The reported result concerns cholesterol levels, not proof that injections prevent heart attacks or strokes, nor whether one injection can replace statins.

How does CTX310 work?

CTX310 uses gene editing to permanently switch off ANGPTL3, a gene in the liver. This reduces blood levels of fatty molecules, including cholesterol and triglycerides.

When LDL remains high, fatty deposits build up in blood-vessel walls, raising the risk of heart attacks and strokes. Oral statins are the most commonly prescribed medicines for high cholesterol. Their chief practical drawback is that patients must take a pill every day for life.

“The issue with a statin is you have to take a pill every day of your life,” said Prof Steve Humphries, a cardiovascular genetics expert at University College London. “So the big advantage of a one-off treatment is: that’s it. You don’t have to worry about any of that stuff.”

Takeaway: The injection changes a liver pathway that controls blood fats, but convenience is not the same as proven long-term safety.

Can a one-time treatment replace daily statins?

Not soon, according to the experts.

Prof Kosh Ray, a cardiologist and public health expert at Imperial College London, put the scale plainly: eight billion people live worldwide, and cardiovascular disease is the leading cause of death. He said health systems need cost-effective ways to reduce that burden.

Ray said statins are safe and well tolerated by most people and will probably remain the standard choice. Humphries described them as cheap as anything, with each tablet costing almost nothing.

Giving gene-editing therapy once does not remove the health system’s workload:

  • Patients need an infusion of CTX310 and of additional medicines needed to prevent an immune reaction to the treatment.
  • Care requires outpatient clinics, staff with the necessary equipment, and training to deliver the therapy.

Ray doubted that this infrastructure could be created now in the UK. He questioned whether clinicians could treat three million people in the country even if each received only one injection in a lifetime.

Although the gene therapy costs are paid for upfront, Ray estimated that daily statins were probably cheaper overall because their cost is spread over time. If CTX310 proves safe over the long term, it could offer another option, especially for people with severe inherited disorders, but the pill is unlikely to vanish.

Takeaway: A single injection avoids lifelong pills, but clinics, staff, immune-suppressing medicines and a large upfront cost make statins hard to displace.

Who might receive CTX310 first?

The relatively high cost of gene-editing treatments may limit their use to people with the greatest need.

All 15 participants had been diagnosed with disorders causing exceptionally high cholesterol or triglycerides. They therefore faced a higher risk of heart attack or stroke than the general population.

Before enrolling, they had tried standard therapies at maximum intensity, likely combinations of high-dose statins and other lipid-lowering drugs. For such patients, gene therapy alone may not bring cholesterol and triglycerides into normal ranges, although a lasting effect could still improve quality of life and reduce the pill burden, Prof Riyaz Patel, a cardiologist at University College London, said.

Ray identified homozygous familial hypercholesterolaemia, or HoFH, as a prime group for a one-off treatment. It affects about 1 in 300,000 people. Those born with the condition have extreme cholesterol from childhood; Ray described their blood as treacle-like and said they can die of a heart attack before their teenage years.

A separate 2026 trial of another gene-editing therapy, VERVE-102, included 35 people, all diagnosed with heterozygous FH, a milder form affecting around 1 in 300 people. Humphries and Patel co-authored the trial. One dose cut LDL cholesterol by 62% in the highest-dose group.

For people with FH, a young-age window exists when cholesterol is high but its consequences have not yet appeared. If CTX310 and VERVE-102 prove safe over the long term, Ray said, early treatment could change the risk trajectory for people with FH.

Takeaway: The first patients likely to benefit are those whose inherited cholesterol levels remain dangerously high despite standard medicines.

Why does timing matter?

Starting treatment early matters for everyone, not only people with FH. Ray calls the prime window the period before disease has appeared.

In future, doctors may be able to estimate a person’s lifetime cardiovascular risk early in life using a polygenic risk score, a calculation based on the person’s overall genetic makeup. Such predictions are not routinely available for the vast majority of the population.

Meanwhile, many people will develop atherosclerosis, the buildup of fatty deposits in artery walls, because of chronically elevated cholesterol. A one-and-done injection that lowers cholesterol by 50% may still be insufficient in advanced disease.

“There’s no single drug on the planet that can lower your cholesterol by 80 or 90 per cent because there are multiple pathways that regulate cholesterol,” Ray said. “For anyone with more advanced disease, you have to combine more than one treatment.”

Takeaway: Earlier treatment may prevent damage, but advanced cholesterol disease will probably require several approaches rather than one injection alone.

What happens next?

Testing of CTX310 continues. Another clinical trial will give one dose to about 90 participants across the US, UK, Australia and New Zealand.

Researchers will evaluate treatment efficacy and safety over a one-year period. That will test the effect in a larger group, but a one-year evaluation would not by itself settle longer-term safety.

A successful trial would mark one step toward longer-lasting control of cholesterol, not yet proof of a permanent cure.

Takeaway: CTX310 remains investigational, and its next test is about repeatability and one-year safety, not approval for routine use.

via sciencefocus.com (Source)

Filed under

  • gene-editing
  • ldl-cholesterol
  • clinical-trials
  • familial-hypercholesterolemia
  • cardiovascular-disease
Share this article:

More from Elena Vasquez

Elena Vasquez

Show full bio

Correspondent covering money, funding and market shifts around general science news at SciBeat.

503 articles

Nearby plates

« Previous articleNext article »